Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | SGK1 | O00141 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489615 | 0.85 | PDPK1 (0.53) | GSK3BFGFR1FGFR2PDPK1HSP90AB1 | |
| SCHEMBL6479380 | 0.83 | JAK2 (0.58) | GSK3BFGFR1FGFR2PDPK1HSP90AB1 | |
| SCHEMBL6479422 | 0.81 | IKBKE (0.48) | GSK3BADORA2AJAK2CDK2 | |
| SCHEMBL6490350 | 0.77 | GSK3B (0.60) | GSK3BFGFR1FGFR2PDPK1HSP90AB1 | |
| SCHEMBL1461708 | 0.77 | GSK3B (1.00) | GSK3BCDK2 | |
| SCHEMBL1180049 | 0.76 | JAK2 (0.59) | GSK3BPDPK1JAK2CDK2GSK3A | |
| SCHEMBL6486529 | 0.75 | GSK3B (0.63) | GSK3BFGFR1FGFR2PDPK1HSP90AB1 | |
| SCHEMBL6477985 | 0.74 | GSK3B (0.56) | GSK3BFGFR1FGFR2PDPK1HSP90AB1 | |
| SCHEMBL6479743 | 0.74 | CDK2 (0.59) | GSK3BFGFR1FGFR2PDPK1HSP90AB1 | |
| SCHEMBL6478798 | 0.73 | JAK2 (0.64) | GSK3BFGFR1PDPK1JAK2GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101962365-A | Aminoindazole derivatives as protein-kinase inhibitors | AVENTIS PHARMA SA | 2011-02-02 | — | — | CN | claimed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | claimed |
| CN-1656078-A | Aminoindazole derivatives as protein kinase inhibitors | AVENTIS PHARMA SA (FR) | 2005-08-17 | — | — | CN | claimed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | claimed |
| EP-1487804-B1 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2014-02-26 | — | — | EP | disclosed |
| CN-101962365-A | Aminoindazole derivatives as protein-kinase inhibitors | AVENTIS PHARMA SA | 2011-02-02 | — | — | CN | disclosed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | disclosed |
| CN-1656078-A | Aminoindazole derivatives as protein kinase inhibitors | AVENTIS PHARMA SA (FR) | 2005-08-17 | — | — | CN | disclosed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | CYP2C8, NR0B2, NR2C2 | GSK3B 2342/4885ADORA2A 369/4885ADORA2B 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.